Oncology drug startup Repare Therapeutics has emerged from stealth with series A funding from investors including Celgene Switzerland.

Canada-based oncology drug developer Repare Therapeutics raised $68m yesterday in a series A round featuring Celgene Switzerland, an affiliate of pharmaceutical firm Celgene.

Venture capital firms Versant Ventures and MPM Capital co-led the round, which included development capital fund Fonds de solidarité FTQ and the Healthcare Venture Fund formed by BDC Capital, a subsidiary of the Business Development Bank of Canada.

Repare was formed by Versant and announced the funding after 18 months in stealth. It is developing oncology drugs…